NeuroMetrix to Exhibit at the Midwest Podiatry ConferenceWALTHAM, Mass.--(BUSINESS WIRE)--Apr. 10, 2012--
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on
the diagnosis and treatment of the neurological complications of
diabetes reported today that it will exhibit at the
Midwest Podiatry
Conference on
April 19-22, 2012 in
Chicago. This is the premier podiatry
conference in the Midwest and is expected to attract over 2,000
podiatrists and related health care professionals. The Conference
promotes podiatric medicine and public health through an annual program
of continuing education and professionally oriented instruction.
NeuroMetrix will showcase NC-stat® DPNCheck™, a
medical device providing a fast, accurate, and quantitative
point-of-care test for the detection of systemic neuropathies such as
diabetic peripheral neuropathy (DPN). DPN affects over 50% of people
with diabetes and can lead to foot ulcers and amputation. Since
commercial launch of NC-stat DPNCheck in late 2011, the company has
attracted an expanding customer base of physicians, including
podiatrists, who have integrated the technology into their medical
practice.
Attendees at the Midwest Podiatry Conference represent a confederation
of podiatric medical associations, including 13 Midwestern states and
the Canadian province of Ontario. The Conference will be held at The
Hyatt Regency Chicago. Further information on the Conference is
available at: http://midwestpodconf.org/.
About NeuroMetrix
NeuroMetrix is a medical device company focused on the diagnosis and
treatment of the neurological complications of diabetes. The Company
currently markets products for the detection, diagnosis, and monitoring
of diabetic neuropathies such as diabetic peripheral neuropathy and
median neuropathy (carpal tunnel syndrome). For more information, please
visit http://www.neurometrix.com.
Source: NeuroMetrix
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief
Financial Officer
neurometrix.ir@neurometrix.com
